Cobo Marcos, Marta
de la Espriella, Rafael
Gayán Ordás, Jara
Zegrí, Isabel
Pomares, Antonia
Llácer, Pau
Fort, Aleix
Rodríguez Chavarri, Adriana
Méndez, Ana
Blázquez, Zorba
Caravaca Pérez, Pedro
Rubio Gracia, Jorge
Recio-Mayoral, Alejandro
García Pinilla, Jose Manuel
Soler, Maria Jose
Garrido González, Ramón
Górriz, Jose Luis
González Rico, Miguel
Castro, Almudena
Núñez, Julio http://orcid.org/0000-0003-1672-7119
Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 12 April 2023
First Online: 24 May 2023
Declarations
:
: All the authors report grants from Astra Zeneca during the conduct of the study. Dr. Cobo Marcos reports personal fees from ASTRA ZENECA, VIFOR PHARMA, NOVARTIS, ROVI, BOEHRINGHER INGELHEIM, NOVONORDISK, ESTEVE and BAYER; Dr Pomares reports personal fees from PFIZER, and support for attending meetings from NOVARTIS AND BAYER, Dr Méndez reports personal fees from ASTRA ZENECA, support for attending meetings from NOVARTIS, and participation on a Data Safety Monitoring Board or Advisory Board from BAYER; Dr Rubio reports personal fees from ASTRA ZENECA, NOVARTIS, BOEHRINGHER INGELHEIM, ESTEVE, and BAYER; Dr Recio reports personal fees from ASTRA ZENECA, NOVARTIS, BOEHRINGHER INGELHEIM, JANSSEN, BAYER, MSD and support for attending meetings from BAYER, MSD and NOVARTIS;. Dr Garía Pinilla reports personal fees from ASTRA ZENECA, VIFOR PHARMA, NOVARTIS, BOEHRINGHER INGELHEIM, PFIZER and BAYER, Dr Soler Romeo reports personal fees from NovoNordisk, Jansen, Boehringer, Mundipharma, Esteve, Fresenius, Ingelheim Lilly, Vifor, ICU Medical, Travere Therapeutics, GE Healthcare, grants and personal fees from AstraZeneca, Editor in Chief of CKJ; In addition, Dr. Soler Romeo has a patent 202131356 issued; Dr Núñez reports, grants from VIFOR PHARMA, personal fees from NOVARTIS, ROVI, BOEHRINGHER INGELHEIM, NOVONORDISK and BAYER. All other authors declare no competing interests.
: This article does not contain any studies with human or animal subjects performed by any of the authors.